Humboldt University of Berlin

About: Humboldt University of Berlin is a education organization based out in Berlin, Germany. It is known for research contribution in the topics: Population & Medicine. The organization has 33671 authors who have published 61781 publications receiving 1908102 citations. The organization is also known as: Humboldt-Universität zu Berlin & Universitas Humboldtiana Berolinensis.

Good laboratory practice: preventing introduction of bias at the bench.

Abstract: Background and Purpose—As a research community, we have failed to demonstrate that drugs which show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Summary of Review—Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Conclusions—Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.

Discovery of very high energy gamma-ray emission coincident with molecular clouds in the W 28 (G6.4-0.1) field

Abstract: We observed the W28 field (for ~40 h) at Very High Energy (VHE) gamma-ray energies (E>0.1 TeV) with the H.E.S.S. Cherenkov telescopes. A reanalysis of EGRET E>100 MeV data was also undertaken. Results from the NANTEN 4m telescope Galactic plane survey and other CO observations have been used to study molecular clouds. We have discovered VHE gamma-ray emission (HESSJ1801-233) coincident with the northeastern boundary of W28, and a complex of sources (HESSJ1800-240A, B and C) ~0.5 deg south of W28, in the Galactic disc. The VHE differential photon spectra are well fit by pure power laws with indices Gamma~2.3 to 2.7. The NANTEN ^{12}CO(J=1-0) data reveal molecular clouds positionally associating with the VHE emission, spanning a ~15 km s^{-1} range in local standard of rest velocity. The VHE/molecular cloud association could indicate a hadronic origin for HESSJ1801-233 and HESSJ1800-240, and several cloud components in projection may contribute to the VHE emission. The clouds have components covering a broad velocity range encompassing the distance estimates for W28 (~2 kpc), and extending up to ~4 kpc. Assuming a hadronic origin, and distances of 2 and 4 kpc for cloud components, the required cosmic ray density enhancement factors (with respect to the solar value) are in the range ~10 to ~30. If situated at 2 kpc distance, such cosmic ray densities may be supplied by a SNR like W28. Additionally and/or alternatively, particle acceleration may come from several catalogued SNRs and SNR candidates, the energetic ultra compact HII region W28A2, and the HII regions M8 and M20 along with their associated open clusters. Further sub-mm observations would be recommended to probe in detail the dynamics of the molecular clouds at velocites >10 km s^{-1}, and their possible connection to W28.

Helicity inversion in responsive foldamers induced by achiral halide ion guests

Abstract: Forthis purpose, the facile access to a responsive foldamerplatform, which allows for convenient tuning of properties(evenunderabioticconditions),isdesirable.Here,wepresentourworkonanovelfamilyofresponsivefoldamers,so-called“clickamers”, and describe their efficient synthesis andinvestigations of their folding behavior under a variety ofconditions. Importantly, we report on an unprecedentedphenomenon of helix inversion

Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality

Abstract: Background and Purpose— The neutral results of the SAINT II trial have again highlighted difficulties translating neuroprotective efficacy from bench to bedside. Animal studies are susceptible to study quality biases, which may lead to overstatement of efficacy. We report the impact of study quality on published estimates of the efficacy of NXY-059 in animal models of stroke. Methods— We conducted a systematic review and stratified meta-analysis of published studies describing the efficacy of NXY-059 in experimental focal cerebral ischemia. Results— Overall, NXY-059 improved infarct volume by 43.3% (95% CI, 34.7 to 52.8). Only 2 of 9 publications reported randomization, concealment of treatment allocation, and blinded outcome assessment. Studies not reporting these quality items gave substantially higher estimates of efficacy than did higher-quality studies. Conclusions— The reported efficacy of NXY-059 in animal models of stroke is confounded by low study quality. The failure of SAINT II highlights the n...